GlassScriptPhysician profile
Stacy Ann Parry
NPI 1952821753
$5,946.40
in general payments reported to CMS, 2019-2025
29 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,006 · 2022: $956 · 2023: $125 · 2024: $562 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,628 · Food and Beverage: $1,296 · Education: $60.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,628.00 |
| Food and Beverage | $1,295.51 |
| Education | $60.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,298.99 | 2025 | Echelon Flex |
| Novo Nordisk INC | $674.26 | 2021-2025 | Wegovy, Ozempic |
| Intuitive Surgical, INC. | $584.92 | 2025 | |
| Medtronic, INC. | $474.66 | 2021-2025 | Sonicision, Signia, Ligasure |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.48 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $334.91 | 2021-2022 | |
| Lilly USA, LLC | $332.17 | 2021-2025 | Zepbound |
| Corcept Therapeutics | $284.36 | 2021-2025 | Korlym |
| Dexcom, INC. | $218.50 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $212.34 | 2021-2022 | |
| Abbvie INC. | $181.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.13 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $113.82 | 2022 | |
| Teleflex LLC | $104.81 | 2025 | Titan Sgs Bailout Chuck |
| Abbott Laboratories | $94.18 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88.26 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $84.12 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $66.54 | 2021 | |
| Merck Sharp & Dohme LLC | $51.69 | 2021-2022 | |
| Radius Health, INC. | $33.59 | 2021 | |
| Currax Pharmaceuticals LLC | $33.29 | 2023 | Contrave, Nexlizet, Nexletol |
| Ultragenyx Pharmaceutical INC. | $27.57 | 2021-2022 | |
| Zealand Pharma US, INC. | $22.60 | 2021 | |
| Amarin Pharma, INC. | $20.08 | 2021 | |
| Amryt Pharma Holdings LTD | $19.04 | 2021 | |
| Horizon Therapeutics Plc | $16.57 | 2021 | |
| Antares Pharma, INC. | $15.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Parry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.